AUSPEX PHARMACEUTICALS, INC. (ASPX) financial statements (2020 and earlier)
Company profile
| Business Address |
3333 N. TORREY PINES COURT LA JOLLA, CA 92037 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2014 | |||
|---|---|---|---|
| ASSETS | |||
| Current Assets | |||
| Cash, cash equivalents, and short-term investments | 145 | ||
| Cash and cash equivalents | 30 | ||
| Short-term investments | 115 | ||
| Receivables | 1 | ||
| Prepaid expense | 0 | ||
| Deferred costs | 0 | ||
| Other undisclosed current assets | 5 | ||
| Total current assets: | 151 | ||
| Noncurrent Assets | |||
| Property, plant and equipment | 0 | ||
| Other noncurrent assets | 0 | ||
| Other undisclosed noncurrent assets | 0 | ||
| Total noncurrent assets: | 0 | ||
| TOTAL ASSETS: | 151 | ||
| LIABILITIES AND EQUITY | |||
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | 14 | ||
| Accounts payable | 7 | ||
| Accrued liabilities | 5 | ||
| Employee-related liabilities | 3 | ||
| Other undisclosed current liabilities | (3) | ||
| Total current liabilities: | 11 | ||
| Noncurrent Liabilities | |||
| Long-term debt and lease obligation | 15 | ||
| Long-term debt, excluding current maturities | 15 | ||
| Liabilities, other than long-term debt | 0 | ||
| Other liabilities | 0 | ||
| Total noncurrent liabilities: | 15 | ||
| Total liabilities: | 26 | ||
| Stockholders' equity | |||
| Stockholders' equity attributable to parent | 121 | ||
| Common stock | 0 | ||
| Additional paid in capital | 246 | ||
| Accumulated deficit | (125) | ||
| Stockholders' equity attributable to noncontrolling interest | 4 | ||
| Total stockholders' equity: | 125 | ||
| TOTAL LIABILITIES AND EQUITY: | 151 | ||
Income statement (P&L) ($ in millions)
| 12/31/2014 | ||
|---|---|---|
| Operating expenses | (50) | |
| Operating loss: | (50) | |
| Nonoperating expense | (9) | |
| Interest and debt expense | (3) | |
| Loss before gain (loss) on sale of properties: | (62) | |
| Other undisclosed net income | 3 | |
| Net loss: | (60) | |
| Net loss attributable to noncontrolling interest | (0) | |
| Net loss available to common stockholders, diluted: | (60) | |
Comprehensive Income ($ in millions)
| 12/31/2014 | ||
|---|---|---|
| Net loss: | (60) | |
| Comprehensive loss: | (60) | |
| Comprehensive loss, net of tax, attributable to noncontrolling interest | (0) | |
| Comprehensive loss, net of tax, attributable to parent: | (60) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.